Cargando…
SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma
Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain constitutively activate EGFR resulting in lung tumorigenesis. Activated EGFR modulates downstream signaling by altering phosphorylation-driven interactions that promote growth and survival. Secretory Carrier Membrane Pro...
Autores principales: | Venugopalan, Abhilash, Lynberg, Matthew, Cultraro, Constance M., Nguyen, Khoa Dang P., Zhang, Xu, Waris, Maryam, Dayal, Noelle, Abebe, Asebot, Maity, Tapan K., Guha, Udayan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514158/ https://www.ncbi.nlm.nih.gov/pubmed/33850265 http://dx.doi.org/10.1038/s41388-021-01764-y |
Ejemplares similares
-
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance
por: Maity, Tapan K., et al.
Publicado: (2023) -
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
por: Venugopalan, Abhilash, et al.
Publicado: (2016) -
Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma
por: Qi, Yue A., et al.
Publicado: (2021) -
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma
por: Qi, Yue A., et al.
Publicado: (2021) -
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)